Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis
Lipids · 2025
DOI: 10.1002/lipd.70018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lipids, 2025. Verfasst von Chao Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Suzhou Medical College of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Cytochrome P-450 CYP2C19, Intracranial Arterial Diseases, Atherosclerosis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Development fund of Affiliated Hospital of Xuzhou Medical UniversityDevelopment fund of Affiliated Hospital of Xuzhou Medical University.
Abstract (Originalsprache)
Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering therapy, potentially influenced by genetic variations, particularly in the CYP2C19 gene. This study at Xuzhou Central Hospital from January 2021 to December 2023 included 151 patients divided into a statin group ( n = 73) and a PCSK9 inhibitor (PCSK9i) group ( n = 78). It evaluated lipid profiles, inflammatory markers, neurological function, and clinical outcomes over a 180‐day follow‐up period, with additional analysis stratified by CYP2C19 genotype. The PCSK9i group demonstrated significant improvements in lipid parameters compared to the statin group, including greater reductions in low‐density lipoprotein cholesterol (LDL‐C) ( p = 0.008), total cholesterol (TC) ( p < 0.001), and triacylglycerols (TAG) ( p = 0.041), along with apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) (both p < 0.001). Inflammatory markers, particularly interleukin‐6 (IL‐6), significantly reduced in the PCSK9i group ( p < 0.001). In the PCSK9i group, CYP2C19 rapid metabolizers achieved greater reductions in LDL‐C ( p = 0.021), ApoB ( p = 0.003), and IL‐6 levels ( p = 0.041) compared to slow metabolizers. Post‐treatment modified Rankin Scale (mRS) scores were significantly lower in rapid metabolizers compared to slow metabolizers ( p = 0.018), though clinical events occurred infrequently in both subgroups. This study demonstrates that PCSK9 inhibitor therapy combined with statins provides enhanced lipid‐lowering and anti‐inflammatory effects compared to statin monotherapy in sICAS patients. While the CYP2C19 genotype may influence specific treatment responses, particularly lipid parameters, its impact on clinical outcomes requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Suzhou Medical College of Soochow University, Suzhou, China.
- Department of Neurology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, China.
- Xuzhou First People's Hospital, Xuzhou, China.
- Department of Neurology, Xuzhou Central Hospital, Xuzhou, China.
ORCID-Profile: Chao Zhao
Förderung
- Development fund of Affiliated Hospital of Xuzhou Medical UniversityDevelopment fund of Affiliated Hospital of Xuzhou Medical University
Zitieren
APA
Zhao, C., Wang, N., Shi, D., Zhou, H., Chen, D., & Chen, G. (2025). Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis. Lipids. https://doi.org/10.1002/lipd.70018
Vancouver
Zhao C, Wang N, Shi D, Zhou H, Chen D, Chen G. Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis. Lipids. 2025. doi:10.1002/lipd.70018
BibTeX
@article{Zhao2025,
author = {Zhao, Chao and Wang, Nuan and Shi, Di and Zhou, Hao and Chen, Dan and Chen, Guofang},
title = {Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis},
journal = {Lipids},
year = {2025},
doi = {10.1002/lipd.70018}
}
EUVIMED